BBNX Short Interest Drops 28% as Stock Surges 21% in a Week

BBNX has moved sharply ahead of its closest peers, gaining 20.6% over the past week against a median of roughly 4.4% for correlated health care equipment names. That divergence makes the short interest story here particularly pointed: bears have been covering, not adding.

Short interest has fallen 27.5% over the past month, dropping from roughly 9.9 million shares in late September to 6.4 million now, equal to 14.6% of free float. The retreat is steep and deliberate. Two weeks ago BBNX carried close to 22% of its float short; today it is down to the mid-teens, a compression that has likely fed some of the week's price move. Borrow conditions corroborate the shift. Availability has expanded dramatically, rising 35% over the week to 673% of current short interest, meaning lenders hold roughly six and a half shares available for every one currently borrowed. That is a loose lending market by any measure, and it removes the mechanical short-squeeze pressure that characterised the stock in mid-September when availability was below 200%.

The analyst community has been building a broadly constructive case. Nine buy-equivalent ratings are on record, and Jefferies initiated at Buy with a $30 target on October 12. Truist raised its target to $28 in late September. Wells Fargo also initiated at Overweight with a $28 target. Bank of America, however, sits at Neutral with a $20 target, essentially in line with the current price of $21.39. The bull argument centres on the iLet closed-loop system, improving gross margins (guided to 57.5% to 59.5%), and the Mint patch-pump clearance expected to widen the addressable market from early 2027. Bears point to an adjusted EBITDA loss of $17.7 million in Q1 and the lowered full-year revenue guidance of $121 million to $126 million, roughly $10 million below where management started the year, attributed to patients deferring ahead of Mint. The stock's EPS momentum ranks in only the 11th percentile over 30 days, and forward earnings yield is in the 28th percentile, reflecting a loss-making business still building toward scale.

Insider activity adds texture worth noting. The net 90-day position from SEC filings shows 157,749 shares sold for a net value of roughly $3 million. Most of those sales were under pre-arranged 10b5-1 plans, including the largest block: the Chief Commercial Officer sold shares in three tranches in September under a scheduled plan. One sale stands apart. CEO Sean Saint sold 16,867 shares on September 2 without a 10b5-1 plan on record, realising around $322,000. Discretionary CEO sales at a pre-revenue growth-stage medical device company typically draw more scrutiny than scheduled disposals, even at these dollar amounts. T. Rowe Price reported holding 16.99% of shares as of September 30, having added nearly 8.9 million shares in the period, making it comfortably the largest institutional holder. Divisadero Street Capital entered the register in July with 2.6 million new shares. Wellington Management and the Vanguard Group both reported exiting their positions entirely earlier this year.

The one prior earnings event with price data shows the stock fell 9.7% on the day and 12% over the five days following the July 2026 report, when the guidance cut was announced. Today's print will test whether the commercial trajectory for the core iLet business, and any update on Mint's launch timing, is enough to hold a stock that has just retraced most of that July decline in a single week.